BUILDING BRIDGES:  The National LeioMyoSarcoma Foundation is collaborating with the FRED HUTCHINSON CANCER RESEARCH CENTER to advocate for the translational research platform: ONCOSCAPE.

On behalf of the Leiomyosarcoma patient community, the National Leiomyosarcoma Foundation (NLMSF) is proud to recognize Oncoscape as an instrumental resource for cancer research and translational medicine. Developed at Fred Hutchinson Cancer Research Center, Oncoscape creates a collaborative platform and community that unites the clinical, genetic, and computational fields in order to enhance the translational potential of precision medicine.  Its suite of interoperable tools empowers researchers and clinicians to explore important cancer-related complexities and offers a unique and intuitive approach to discover novel patterns between clinical and molecular data.

In a collaborative alliance, the NLMSF and Oncoscape aim to promote cross-disciplinary research and personalized patient care for the Leiomyosarcoma community by establishing an end-to-end solution that integrates tools, resources, and people.  Working together, we can lay the foundation for reproducible research and deliver emerging technologies in order to make more informed clinical decisions and ultimately improve patient outcomes.

Guiding productive research and therapeutic directions is critical for all cancers, and certainly Sarcomas.  We advocate the mission and vision of Oncoscape in fulfilling this need.

Video: Octotales • Fred Hutch

Oncoscape was created at the Fred Hutchinson Cancer Research Center (FHCRC), under the auspices of the Seattle Translational Tumor Research Initiative (STTR).